Zulresso Is Sage’s First Step In Postpartum Depression Treatment
I.V. Zulresso is the first US FDA-approved drug for postpartum depression (PPD) and Sage's first commercial product – with a list price of $34,000. It will help the company build a presence in PPD as it completes late-stage development for oral candidate SAGE-217.
You may also be interested in...
The companies reported positive Phase III data in postpartum depression, a market opportunity of up to half a million women in the US with a condition that remains underdiagnosed.
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption
When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.